文献速递重症综合管理与镇静镇痛

成人重症患者右美托咪定撤药反应发生率:一项先导研究

Incidence of Dexmedetomidine Withdrawal in Adult Critically Ill Patients: A Pilot Study.
PubMed 文献 · Crit Care Explor · 2019-08-09
一句话结论前瞻性观察显示,接受右美托咪定至少3天的成人重症患者中64%出现撤药反应表现,峰值剂量>0.8 µg/kg/hr与累积日剂量>12.9 µg/kg/d可能与更高发生率相关。

该前瞻性观察研究纳入2017年11月至2018年12月在某三级医院内科-外科、心胸外科和神经外科ICU中接受右美托咪定持续输注至少3天的成人重症患者42例。撤药评估在基线及减量期间至少每日进行,采用ICU意识模糊评估法(CAM-ICU)、Richmond躁动-镇静量表(RASS)、撤药评估工具-1(WAT-1)及生命体征;满足CAM-ICU阳性、RASS>+1、WAT-1阳性、心动过速(心率>90次/分)、高血压(收缩压>140 mmHg或平均动脉压>90 mmHg)中至少两项即判定为右美托咪定撤药阳性。结果显示64%患者出现撤药表现,撤药阳性者中最常见的症状为谵妄(93%)、高血压(48%)和躁动(33%);峰值剂量>0.8 µg/kg/hr和累积日剂量>12.9 µg/kg/d与更高撤药发生率相关,而慢性阿片耐受与撤药发生率无相关性。作者建议对长期右美托咪定输注患者进行定期筛查。

要点

  • 42例接受右美托咪定至少3天的成人重症患者中,64%出现符合预设标准的撤药表现。
  • 撤药阳性患者中最常见表现为谵妄(93%)、高血压(48%)和躁动(33%)。
  • 峰值剂量>0.8 µg/kg/hr和累积日剂量>12.9 µg/kg/d与更高撤药发生率相关,而治疗时长未显示相关。
  • 慢性阿片耐受与撤药发生率无相关性。
  • 作者建议对长期右美托咪定输注患者进行定期筛查以确保安全有效使用。

适用人群与场景

  • 某三级医院内科-外科、心胸外科和神经外科ICU中接受右美托咪定持续输注至少3天的成人重症患者。

诊断标准与关键阈值

  • 右美托咪定撤药阳性判定标准:满足以下至少两项——CAM-ICU阳性、RASS>+1、WAT-1评估阳性、心动过速(心率>90次/分)、高血压(收缩压>140 mmHg或平均动脉压>90 mmHg)。
  • 撤药指标在基线及右美托咪定减量期间至少每日评估一次。

红旗征与不能漏的情况

  • 撤药阳性患者中最常见的表现为谵妄(93%)、高血压(48%)和躁动(33%),需按预设标准识别并处理。

研究设计与关键结果

  • 前瞻性观察研究纳入42例成人重症患者,64%出现右美托咪定撤药表现。
  • 全部患者右美托咪定使用中位时间为9.6天(5.8-12.7天),中位剂量为0.8 µg/kg/hr(0.5-1 µg/kg/hr)。
  • 撤药阳性患者中最常见症状为谵妄(93%)、高血压(48%)和躁动(33%)。
  • 慢性阿片耐受与撤药症状发生率无相关性。
  • 峰值右美托咪定剂量>0.8 µg/kg/hr和累积日剂量>12.9 µg/kg/d与更高撤药发生率相关。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究(先导研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议对接受长期右美托咪定输注的患者进行定期筛查,以确保在重症患者中安全有效使用。
  • 峰值剂量>0.8 µg/kg/hr和累积日剂量>12.9 µg/kg/d可能与更高撤药发生率相关,而治疗时长未显示相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: To determine the incidence of dexmedetomidine withdrawal in adult critically ill patients.

DESIGN: This was a prospective, observational study of patients from November 2017 to December 2018.

SETTING: Medical-surgical, cardiothoracic, and neurosurgical ICUs in a tertiary care hospital.

PATIENTS: Adult critically ill patients on dexmedetomidine infusions for at least 3 days.

INTERVENTIONS: Indicators of withdrawal were assessed at baseline and at least daily during the dexmedetomidine wean period. Delirium was assessed using the Confusion Assessment Method for the ICU. Sedation was assessed using the Richmond Agitation-Sedation Scale. The Withdrawal Assessment Tool-1 was performed and vital signs were recorded during each assessment. Patients were considered positive for dexmedetomidine withdrawal if they had two or more of the following symptoms: positive Confusion Assessment Method for the ICU, Richmond Agitation-Sedation Scale greater than +1, positive Withdrawal Assessment Tool-1 assessment, tachycardia (heart rate > 90 beats/min), and hypertension (systolic blood pressure > 140 mm Hg or mean arterial pressure > 90).

MEASUREMENTS AND MAIN RESULTS: Forty-two patients were included in the study, with 64% of patients experiencing signs of dexmedetomidine withdrawal. The median time on dexmedetomidine for all patients was 9.6 days (5.8-12.7 d), and the median dose of dexmedetomidine received was 0.8 µg/kg/hr (0.5-1 µg/kg/hr). Of the patients who were positive for withdrawal, the most prevalent withdrawal symptoms observed included delirium, hypertension, and agitation (93%, 48%, and 33%, respectively). We found no correlation between chronic opioid tolerance and incidence of withdrawal symptoms. Peak dexmedetomidine doses greater than 0.8 µg/kg/hr and cumulative daily doses of dexmedetomidine greater than 12.9 µg/kg/d were associated with a higher incidence of withdrawal.

CONCLUSIONS: The majority of patients in our study demonstrated signs that may be indicative of dexmedetomidine withdrawal. Peak and cumulative daily dexmedetomidine dose, rather than duration of therapy, may be associated with a higher incidence of withdrawal signs. Regular screening of patients on prolonged dexmedetomidine infusions is recommended to ensure safe and effective use in critically ill patients.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Bouajram RH, Bhatt K, Croci R, et al. Incidence of Dexmedetomidine Withdrawal in Adult Critically Ill Patients: A Pilot Study. Crit Care Explor. 2019. PMID: 32166276. doi:10.1097/CCE.0000000000000035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。